Limits...
The association of HMGB1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: a meta-analysis and literature review.

Zhang L, Han J, Wu H, Liang X, Zhang J, Li J, Xie L, Xie Y, Sheng X, Yu J - PLoS ONE (2014)

Bottom Line: The overall survival (OS) was significantly shorter in HCC patients with high HMGB1 expression compared those with low HMGB1 expression and the pooled HR was 1.31 with 95% CI 1.20-1.44, Z = 5.82, p<0.0001.The results of this meta-analysis suggest that HMGB1 mRNA and protein tissue levels in the patients with HCC are significantly higher than those in para-tumor and normal liver tissues respectively.Tissue HMGB1 overexpression is a potential biomarker for HCC diagnosis, and it is significantly associated with the prognosis of patients with HCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, School of Medicine and life Science, University of Jinan-Shandong Academy of Medical Science, Jinan, Shandong, P.R. China.

ABSTRACT

Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer, and it is the second most common cancer-related mortality globally. The prognostic value of high mobility group box 1 (HMGB1) remains controversial. The purpose of this study is to conduct a meta-analysis and literature review to evaluate the association of HMGB1 expression with the prognosis of patients with HCC.

Methods: A detailed literature search was made in Medline, Google Scholar and others for related research publications. The data were extracted and assessed by two reviewers independently. Analysis of pooled data were performed, Hazard Ratio (HR) and mean difference with corresponding confidence intervals (CIs) were calculated and summarized respectively.

Results: 10 relevant articles were included for this meta-analysis study. HMGB1 mRNA levels in HCC were significantly higher than those in normal (p<0.00001) and para-tumor tissues (p = 0.002) respectively. The protein levels of HMGB1 in HCC were significantly higher than those in para-tumor tissues (p = 0.005). Two studies reported the serum HMGB1 levels in patients with HCC of TNM stages, and indicating significantly different between stage I and II, stage II and III, as well as stage III and IV (two studies showed p<0.01 and p<0.001 respectively). The overall survival (OS) was significantly shorter in HCC patients with high HMGB1 expression compared those with low HMGB1 expression and the pooled HR was 1.31 with 95% CI 1.20-1.44, Z = 5.82, p<0.0001. Two additional studies showed that there were higher serum HMGB1 levels in patients with chronic hepatitis than those in healthy people (p<0.05).

Conclusions: The results of this meta-analysis suggest that HMGB1 mRNA and protein tissue levels in the patients with HCC are significantly higher than those in para-tumor and normal liver tissues respectively. Tissue HMGB1 overexpression is a potential biomarker for HCC diagnosis, and it is significantly associated with the prognosis of patients with HCC.

Show MeSH

Related in: MedlinePlus

Forest plot for HMGB1 protein/GADPH in HCC and para-tumor tissue.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4214718&req=5

pone-0110626-g004: Forest plot for HMGB1 protein/GADPH in HCC and para-tumor tissue.

Mentions: HMGB1 mRNA level in HCC was significantly higher than in normal and para-tumor tissues respectively. The pooled mean difference for HCC versus normal liver tissue was 0.38, (95% CI 0.22–0.54, Z = 4.59, p<0.00001, heterogeneity I2 = 91%, Figure 2) and for HCC versus para-tumor, mean difference was 0.31, (95% CI 0.12–0.51, Z = 3.12, p = 0.002, heterogeneity I2  = 93%, Figure 3). The protein level of HMGB1 in HCC was significantly higher than those in para-tumor tissues, the pooled mean difference was 0.51 with 95% CI 0.16–0.86, (Z = 2.83, p = 0.005, heterogeneity I2 = 98%, Figure 4). Figure 5 showed the result of a meta-analysis of hazard ratios (HR) of HMGB1 high expression and low expression in the survival of patients with HCC. The overall survival (OS) was significantly shorter in HCC patients with high HMGB1 expression compared those with low HMGB1 expression, and the pooled HR was 1.31 with 95% CI 1.20–1.44, (Z = 5.82, p<0.0001, heterogeneity I2 = 20%, Figure 5).


The association of HMGB1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: a meta-analysis and literature review.

Zhang L, Han J, Wu H, Liang X, Zhang J, Li J, Xie L, Xie Y, Sheng X, Yu J - PLoS ONE (2014)

Forest plot for HMGB1 protein/GADPH in HCC and para-tumor tissue.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4214718&req=5

pone-0110626-g004: Forest plot for HMGB1 protein/GADPH in HCC and para-tumor tissue.
Mentions: HMGB1 mRNA level in HCC was significantly higher than in normal and para-tumor tissues respectively. The pooled mean difference for HCC versus normal liver tissue was 0.38, (95% CI 0.22–0.54, Z = 4.59, p<0.00001, heterogeneity I2 = 91%, Figure 2) and for HCC versus para-tumor, mean difference was 0.31, (95% CI 0.12–0.51, Z = 3.12, p = 0.002, heterogeneity I2  = 93%, Figure 3). The protein level of HMGB1 in HCC was significantly higher than those in para-tumor tissues, the pooled mean difference was 0.51 with 95% CI 0.16–0.86, (Z = 2.83, p = 0.005, heterogeneity I2 = 98%, Figure 4). Figure 5 showed the result of a meta-analysis of hazard ratios (HR) of HMGB1 high expression and low expression in the survival of patients with HCC. The overall survival (OS) was significantly shorter in HCC patients with high HMGB1 expression compared those with low HMGB1 expression, and the pooled HR was 1.31 with 95% CI 1.20–1.44, (Z = 5.82, p<0.0001, heterogeneity I2 = 20%, Figure 5).

Bottom Line: The overall survival (OS) was significantly shorter in HCC patients with high HMGB1 expression compared those with low HMGB1 expression and the pooled HR was 1.31 with 95% CI 1.20-1.44, Z = 5.82, p<0.0001.The results of this meta-analysis suggest that HMGB1 mRNA and protein tissue levels in the patients with HCC are significantly higher than those in para-tumor and normal liver tissues respectively.Tissue HMGB1 overexpression is a potential biomarker for HCC diagnosis, and it is significantly associated with the prognosis of patients with HCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, School of Medicine and life Science, University of Jinan-Shandong Academy of Medical Science, Jinan, Shandong, P.R. China.

ABSTRACT

Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer, and it is the second most common cancer-related mortality globally. The prognostic value of high mobility group box 1 (HMGB1) remains controversial. The purpose of this study is to conduct a meta-analysis and literature review to evaluate the association of HMGB1 expression with the prognosis of patients with HCC.

Methods: A detailed literature search was made in Medline, Google Scholar and others for related research publications. The data were extracted and assessed by two reviewers independently. Analysis of pooled data were performed, Hazard Ratio (HR) and mean difference with corresponding confidence intervals (CIs) were calculated and summarized respectively.

Results: 10 relevant articles were included for this meta-analysis study. HMGB1 mRNA levels in HCC were significantly higher than those in normal (p<0.00001) and para-tumor tissues (p = 0.002) respectively. The protein levels of HMGB1 in HCC were significantly higher than those in para-tumor tissues (p = 0.005). Two studies reported the serum HMGB1 levels in patients with HCC of TNM stages, and indicating significantly different between stage I and II, stage II and III, as well as stage III and IV (two studies showed p<0.01 and p<0.001 respectively). The overall survival (OS) was significantly shorter in HCC patients with high HMGB1 expression compared those with low HMGB1 expression and the pooled HR was 1.31 with 95% CI 1.20-1.44, Z = 5.82, p<0.0001. Two additional studies showed that there were higher serum HMGB1 levels in patients with chronic hepatitis than those in healthy people (p<0.05).

Conclusions: The results of this meta-analysis suggest that HMGB1 mRNA and protein tissue levels in the patients with HCC are significantly higher than those in para-tumor and normal liver tissues respectively. Tissue HMGB1 overexpression is a potential biomarker for HCC diagnosis, and it is significantly associated with the prognosis of patients with HCC.

Show MeSH
Related in: MedlinePlus